

South Australia

Trans-Tasman Mutual Recognition (South Australia) Regulations 2015

under the *Trans-Tasman Mutual Recognition (South Australia) Act 1999*

Contents

- 1 Short title
- 3 Interpretation
- 4 Temporary exemptions—synthetic drugs
- 5 Temporary exemption—MDMB-CHMICA

Schedule 1—Temporary exemptions—synthetic drugs

Legislative history

1—Short title

These regulations may be cited as the *Trans-Tasman Mutual Recognition (South Australia) Regulations 2015*.

3—Interpretation

In these regulations—

Act means the *Trans-Tasman Mutual Recognition (South Australia) Act 1999*.

4—Temporary exemptions—synthetic drugs

- (1) For the purposes of section 5 of the Act and section 46 of the Commonwealth Act—
 - (a) the substances specified in Schedule 1 are declared to be exempt from the operation of the Commonwealth Act; and
 - (b) the provisions of the *Controlled Substances (Controlled Drugs, Precursors and Plants) Regulations 2014* inserted by the *Controlled Substances (Controlled Drugs, Precursors and Plants) Variation Regulations 2015* are declared to be exempt from the operation of the Commonwealth Act.
- (2) The exemptions from the Commonwealth Act under subregulation (1) have effect for a period of 12 months following the commencement of this regulation.

5—Temporary exemption—MDMB-CHMICA

- (1) For the purposes of section 5 of the Act and section 46 of the Commonwealth Act—
 - (a) the substance methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate (MDMB-CHMICA) and any preparation containing that substance are declared to be exempt from the operation of the Commonwealth Act; and

- (b) the provisions of the *Controlled Substances (Controlled Drugs, Precursors and Plants) Regulations 2014* referring to the substance specified in paragraph (a) (inserted by regulation 4(4) of the *Controlled Substances (Controlled Drugs, Precursors and Plants) Variation Regulations 2015*) are declared to be exempt from the operation of the Commonwealth Act.
- (2) The exemptions from the Commonwealth Act under subregulation (1) have effect for a period of 12 months following the commencement of this regulation.

Schedule 1—Temporary exemptions—synthetic drugs

1-pentyl-3-(Adamant-1-yl)indole (AB-001)
N-(Adamant-1-yl)-1-(5-fluoropentyl)-1*H*-indole-3-carboxamide (STS-135)
3-(1-Adamantoyl)-indoles
N-(1-Adamantyl)-1-(5-fluoropentyl)-1*H*-indazole-3-carboxamide (5F-AKB48)
N-(1-Adamantyl)-indazole-3-carboxamides
N-allyl-N-[2-(5-Methoxy-1*H*-indol-3-yl)ethyl]prop-2-en-1-amine(*N,N*-diallyl-5-Methoxytryptamine or 5-MeO-DALT)
N-[1-Aminocarbonyl]-2-methylpropyl]-1-(cyclohexylmethyl)-1*H*-indazole-3-carboxamide (AB-CHMINACA)
N-[1-(Aminocarbonyl)-2-methylpropyl]-1-pentyl-1*H*-indazole-3-carboxamide (AB-PINACA)
N-[1-(Aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]-1*H*-indazole-3-carboxamide (AB-FUBINACA)
1-(1,3-Benzodioxol-5-yl)-2-(ethylamino)propan-1-one (Ethylone)
1-(1,3-Benzodioxol-5-yl)-2-(methylamino)butan-1-one (Butylone)
1-(1,3-Benzodioxol-5-yl)-2-(methylamino)pentan-1-one (Pentylone)
3,4 dichloro-N-[1-(dimethylamino)cyclohexylmethyl]benzamide (AH-7921)
(3-Diethylamino-2,2-dimethylpropyl)-4-aminobenzoate (Dimethocaine)
6,7-dihydro-5*H*-cyclopenta[*f*][1,3]benzodioxol-6-amine (5,6-Methylenedioxy-2-aminoindane or MDAI)
2-(2,5-Dimethoxyphenyl)-*N*-(2-methoxybenzyl)ethanamine (25H-NBOMe)
2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)
5-(1,1-dimethyloctyl)-2-[3-hydroxycyclohexyl]-phenol (cannabicyclohexanol)
5-(1,1-dimethylheptyl)-2-[3-hydroxycyclohexyl]-phenol (CP-47,497)
2-ethylamino-1-(4-methylphenyl)propan-1-one (4-methylethcathinone or 4-MEC)
N-(1-Fenchyl)-indole-3-carboxamides
2-(4-Fluoro-2,5-dimethoxyphenyl)-1-aminoethane (2C-F)
2-(4-Fluoro-2,5-dimethoxyphenyl)-*N*-(2-methoxybenzyl)ethanamine (25F-NBOMe)
Indazole-3-carboxamides

(Indol-3-yl)-(2,2,3,3-tetra-alkylcyclopropyl)methanones

Indole-3-carboxylic acid, quinolinyl esters

7-Methoxy-1-(2-morpholinoethyl)-N-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl)-1H-indole-3-carboxamide (N-Fenchyl-1-(2-morpholinoethyl)-7-methoxyindole-3-carboxamide or UR-12)

1-(4-methylphenyl)-2-(1-pyrrolidinyl)-1-propanone

(4'-Methyl- α -pyrrolidinopropiophenone or 4-MePPP or M α PPP)

Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (NM2201)

1-phenyl-2-(1-pyrrolidinyl)-1-pentanone (alpha-PVP or alpha-pyrrolidinovalerophenone)

1-pentyl-N-tricyclo[3.3.1.1^{3,7}]dec-1-yl-1H-indole-3-carboxamide (N-(1-Adamantyl)-1-pentyl-1H-indole-3-carboxamide or SDB-001 or APICA)

Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5F-PB-22)

Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-22)

Legislative history

Notes

- For further information relating to the Act and subordinate legislation made under the Act see the Index of South Australian Statutes or www.legislation.sa.gov.au.

Legislation revoked by principal regulations

The *Trans-Tasman Mutual Recognition (South Australia) Regulations 2015* revoked the following:

Trans-Tasman Mutual Recognition (South Australia) Regulations 2013

Principal regulations and variations

New entries appear in bold.

Year	No	Reference	Commencement
2015	188	<i>Gazette 23.7.2015 p3548</i>	23.7.2015: r 2
2015	244	<i>Gazette 3.12.2015 p5163</i>	3.12.2015: r 2

Provisions varied

New entries appear in bold.

Entries that relate to provisions that have been deleted appear in italics.

Provision	How varied	Commencement
<i>r 2</i>	<i>omitted under Legislation Revision and Publication Regulations 2002</i>	<i>3.12.2015</i>
r 5	inserted by 244/2015 r 4	3.12.2015
<i>Sch 2</i>	<i>omitted under Legislation Revision and Publication Regulations 2002</i>	<i>3.12.2015</i>